Conference Coverage
Conference Coverage
Fresh evidence of methotrexate efficacy in psoriatic arthritis
The first-ever trial set up to test the hypothesis that a tumor necrosis factor inhibitor plus methotrexate have synergistic efficacy in psoriatic...
Conference Coverage
60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasis
After 60 weeks of continuous ixekizumab therapy, patients with moderate-to-severe plaque psoriasis had PASI 75 scores of 87%.
Conference Coverage
NNTs show once-unimaginable psoriasis outcomes now readily attainable
Interleukin-17 antagonists achieve PASI-90 response in a majority of psoriasis patients.
Conference Coverage
Registry shows no increased cancer risk with biologics for psoriasis
Updated results from PSOLAR registry.
Conference Coverage
Consider comorbidities in psoriasis treatment for better outcomes
Emerging data increasingly link psoriasis with cardiovascular disease, diabetes, and depression, leading one expert to suggest a more integrated...
Conference Coverage
VIDEO: IL-17 antagonists continue reshaping psoriasis therapy in 2016
IL-17 antagonists should continue to reshape psoriasis therapy in 2016, Dr. Craig Leonardi predicted.
Conference Coverage
VIDEO: Humor, psychology turn noncompliance into better outcomes
Dr. Steven Feldman recounts humorous anecdotes that helped him understand what it takes to get patients to comply with treatment.
Conference Coverage
VIDEO: Ken Gordon’s pro tips on using biologics in psoriasis
“Look at the patient in front of you.” That’s the advice from Dr. Kenneth B. Gordon on using biologics in harder-to-treat patients with psoriasis...
Conference Coverage
EADV: Family history of cardiovascular disease is key in psoriasis patients
A family history of cardiovascular disease takes on extra importance in assessing cardiovascular risk in young adult psoriasis patients.
Conference Coverage
EADV: New oral psoriasis drug shows excellent safety
Key clinical point: The oral A3 adenosine receptor agonist CF1-1 shows promise as a potential first-line systemic therapy for moderate to severe...